Icovamenib for Type 2 Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase 2, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes who are not achieving glycemic targets despite antihyperglycemic medications.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive icovamenib or placebo in addition to their current antihyperglycemic medications for 12 weeks
Continuation
Participants continue on their currently prescribed antihyperglycemic medication(s) after the initial 12-week treatment phase
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Icovamenib
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
icovamenib 100 mg QD in addition to their currently prescribed antihyperglycemic medication(s) for 12 weeks. At Week 12, participants will continue on their currently prescribed antihyperglycemic medication(s). The total duration of the trial is approximately 56 weeks
icovamenib 100 mg matching placebo QD in addition to their currently prescribed antihyperglycemic medication(s) for 12 weeks. At Week 12, participants will continue on their currently prescribed antihyperglycemic medication(s). The total duration of the trial is approximately 56 weeks
Find a Clinic Near You
Who Is Running the Clinical Trial?
Biomea Fusion Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.